ArticleCancer2025
Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-world experience with ipilimumab in combination with nivolumab in advanced sarcoma: a retrospective analysis including ultra-rare sarcomas.The oncologist · 2026Article
- Review
- Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma.Frontiers in immunology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) in unselected sarcomas yield limited response rates and tumor control. Long-term responders have however been reported, suggesting a critical challenge in refining patient selection, by identifying reliable predictive factors for response.
methodsThe authors conducted a multicenter, retrospective study of patients with advanced sarcomas treated with ICIs in six French reference sarcoma centers. The study assessed efficacy and safety, as well as clinical and biological variables associated with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
resultsA total of 272 patients were included in the analysis. The ORR was 17%, with 16% partial responses and 1% complete responses. Stable disease (SD) occurred in 33% of patients, resulting in a disease control rate of 49%. Median PFS was 2.7 months (95% confidence interval [CI], 2.5-3.4), with 28% of patients showing PFS >6 months and 13% with PFS >12 months. Median OS was 13.5 months (95% CI, 11.0-17.3). The safety profile was consistent with that of clinical trials, with 5% of patients experiencing grade ≥3 adverse events and 10% discontinuing treatment due to toxicity. Poorer outcomes were associated with high Eastern Cooperative Oncology Group performance status (≥1), cyclophosphamide coadministration, and high derived neutrophil-to-lymphocyte ratio. Anti-programmed death-ligand 1 (PD-L1) therapies were associated with shorter OS compared to anti-PD-1. Histotypes such as alveolar soft part sarcoma (ASPS) had better survival, whereas dedifferentiated liposarcoma had poorer outcomes.
conclusionsDespite a short median PFS, certain histological subtypes, including ASPS, chordomas, SMARCA4-deficient tumors, gastro-intestinal stromal tumor, and NF1 mutations, showed strong activity signals, indicating long-term responses in some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.